Seladelpar is a peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).
How to Use Seladelpar
Pre-Administration Assessment
Liver function tests (alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin, alkaline phosphatase [ALP]).
Renal function assessment.
Bone mineral density test (to evaluate fracture risk).
Confirmation of concurrent biliary obstruction.
Standard Dosing Regimen
The recommended dose is 10mg orally once daily, which can be taken with or without food. The medication should be taken at a fixed time every day to maintain a stable plasma drug concentration.
For patients using bile acid sequestrants concurrently, seladelpar should be taken either 4 hours before or 4 hours after the bile acid sequestrant. Every effort should be made to extend the interval between the two medications.
Dosage Adjustment of Seladelpar
Adjustment Based on Therapeutic Response
First, confirm patient adherence to the medication.
Check for potential drug-drug interactions.
Evaluate the presence of biliary obstruction.
Dose escalation is not recommended (doses exceeding 10mg may increase the risk of elevated liver enzymes).
Adjustment Based on Safety
When ALT or AST > 3 times the upper limit of normal (ULN): Discontinue the medication immediately. After liver enzymes return to normal, resumption at the original dose or a reduced dose may be considered.
When total bilirubin > 2 times ULN: Discontinue the medication permanently.
When a fracture occurs: Evaluate the risk-benefit ratio of continuing treatment.
When biliary obstruction occurs: Interrupt treatment until the obstruction is resolved.
Seladelpar Use in Special Populations
Patients with Hepatic Impairment
Child-Pugh Class A: No dosage adjustment is required.
Child-Pugh Class B/C: Use is not recommended.
Decompensated cirrhosis: Contraindicated.
Patients with Renal Impairment
Mild to moderate renal impairment: No dosage adjustment is required.
Severe renal impairment and dialysis patients: Safety data are limited; use with caution.
Elderly Patients
No dosage adjustment is needed for patients aged 65 years and above. However, clinical experience in patients aged 75 years and above is limited, so enhanced monitoring is recommended.
Pregnant and Lactating Women
Pregnancy: Sufficient human data are lacking. Animal studies have shown that high doses may affect fetal development.
Lactation: Whether the drug is excreted into human milk is unknown. The risks and benefits should be weighed before deciding to use the medication.
